Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Ertugliflozin shows significant A1C reductions in patients with type 2 diabetes in two phase 3 trials
Two phase 3 clinical trials evaluating ertugliflozin for the treatment of type 2 diabetes met their primary endpoints demonstrating statistically significant reductions in blood glucose (A1C).
Sirukumab meets both co-primary endpoints in rheumatoid arthritis study
A phase III clinical trial evaluating sirukumab in adult patients with moderately to severely active rheumatoid arthritis (RA) met both co-primary endpoints.
Blood test that detects early Alzheimer's disease developed
Researchers have developed a blood test that leverages the body's immune response system to detect an early stage of Alzheimer's disease - referred to as the mild cognitive impairment (MCI...
U.S. regulator says too many drugmakers chasing same cancer strategy
By Deena BeasleyA new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.
Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
Lexington, Massachusetts, US – June 14, 2016 – Shire plc (LSE.
FDA, Teva Pharmaceuticals announce sales suspension of Zecuity patch
The FDA and Teva Pharmaceuticals announced that Teva has voluntarily suspended sales, marketing and distribution of the Zecuity patch.
U.S. panel backs approval for Merck infectious diarrhea drug
Merck & Co's experimental drug to treat the most common cause of hospital-associated infectious diarrhea warrants approval, an advisory panel to the U.
Ultragenyx, Takeda partner to develop rare genetic disease therapies
Ultragenyx Pharmaceutical and Takeda Pharmaceutical have partnered to develop and commercialize therapies for rare genetic diseases.
FluoroPharma announces letter of intent to buy Ground Fluor Pharmaceuticals
FluoroPharma Medical has entered into a nonbinding letter of intent to acquire Ground Fluor Pharmaceuticals (GFP).
Biogen to continue development of opicinumab MS drug despite failure in phase II trial
Biogen said it will continue clinical development of opicinumab (anti-LINGO-1) even though the multiple sclerosis (MS) candidate missed its primary endpoint in a phase II trial.
Aspen to Buy Anesthetics From AstraZeneca for $520 Million
Aspen Pharmacare Holdings Ltd.
Merck to Acquire Afferent Pharmaceuticals
KENILWORTH, N.
30
31
32
33
34
35
36
37
38
